Genetic variants may affect treatment response to commonly prescribed type 2 diabetes medication

Study’s findings could lead to personalized strategies for diabetes prevention and care treatment.

2023-06-02

(Press-News.org) BOSTON – Various medications can be prescribed to lower blood sugar levels in individuals at high risk for developing type 2 diabetes, but it’s often unclear which patients will benefit most from which drugs.

In a study published in Diabetologia, investigators at Massachusetts General Hospital (MGH), founding member of Mass General Brigham (MGB), identified genetic variants associated with response to two such drugs: metformin and glipizide. The findings may help personalize care to prevent and treat type 2 diabetes.

Current available treatments for type 2 diabetes do not consider an individual’s underlying genetics or disease pathophysiology, making it a burden to develop tailored interventions.

The team of investigators, co-led by Josephine Li, MD, endocrinologist in the Diabetes Unit at MGH and an Instructor in Medicine at Harvard Medical School, studied whether a genome-wide approach could unravel new pharmacogenetic associations and develop insight to understand the relevance of known genetic risk factors for type 2 diabetes.

In the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH), researchers collected genetic data on 1,000 individuals at risk of developing type 2 diabetes who received a short course of metformin and glipizide. The team also documented patients’ blood sugar and insulin levels after receiving these drugs.

“We performed a genome-wide association study to comprehensively identify genetic variants associated with drug response. We also tested the influence of previously reported genetic variants for type 2 diabetes and glycemic traits on SUGAR-MGH outcomes,” says Dr. Li. “Our study was unique in that over a third of SUGAR-MGH participants were of non-European descent, in contrast to existing pharmacogenetic genome-wide association studies.”

Five genetic variants were significantly associated with acute response to metformin or glipizide. Three were more common in participants of African ancestry. One of these African ancestry–specific variants (called rs111770298) was confirmed in the Diabetes Prevention Program, where individuals with this variant experienced a weaker response to metformin treatment than participants without.

“Understanding the impact of ancestry-specific variants can help guide and tailor treatment selection for population subgroups in the future,” notes Li.

In a separate analysis, another variant (called rs703972), previously known to help protect against type 2 diabetes, was associated with higher levels of active glucagon-like peptide 1, a hormone that stimulates insulin secretion and reduces appetite.

“Next steps include functional experiments to confirm the implications of the novel genetic variants we’ve identified that are associated with the body’s response to these glucose-lowering therapies,” says Li.

“SUGAR-MGH is designed to allow investigators to use two commonly-used drugs with different mechanisms of action to probe the role of specific genes on glucose regulation,” says co–senior author Jose C. Florez, MD, PhD, chief of the Endocrine Division and the Diabetes Unit at MGH and a professor of Medicine at Harvard Medical School.

The scientists made their findings available as a public resource to enable other researchers to complement their work.

Additional authors include co–lead authors Laura N. Brenner and Varinderpal Kaur; co–senior author Josep M. Mercader; and Katherine Figueroa, Philip Schroeder, Alicia Huerta‐Chagoya, Miriam S. Udler, and Aaron Leong.

This work was supported by National Institutes of Health, the Joslin Clinical Research Center, and the Harvard Catalyst: the Harvard Clinical and Translational Science Center.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In July 2022, Mass General was named #8 in the U.S. News & World Report list of "America’s Best Hospitals." MGH is a founding member of the Mass General Brigham healthcare system.

END

ELSE PRESS RELEASES FROM THIS DATE:

UC Davis C-STEM trains Redlands teachers on bringing computer science into math

2023-06-02

Twenty-five teachers from Redlands Unified School District in southern California recently completed training in integrating computer science into math education through a joint program offered by the University of California, Davis, and UC Riverside Extension. The Joint Computer Science Supplementary Teaching Credential Authorization Program has helped Redlands address gaps in student opportunity and achievement, and teachers’ skills. “Improving math instruction for student success is the most challenging task in education. Redlands partnered with UC Davis to make math instruction with ...

Changes in RECIST tumor measures correlate linearly with survival in patients treated with checkpoint inhibitors

2023-06-02

The Response Evaluation Criteria In Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories (complete or partial response, or stable or progressive disease) based on the percent of change in the sum of the longest diameters of a set of target lesions. An analysis of data from the SWOG S1609 trial conducted by the NCI-funded National Clinical Trials Network (NCTN) finds that in patients treated with immune checkpoint inhibitors, survival times correlate linearly with that change, rather than exhibiting threshold effects ...

Bench-to-field study identifies pesticides that could influence Parkinson's disease

2023-06-02

A new study from researchers in the Khurana lab at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, in close collaboration with researchers from the Ritz lab at UCLA and the Rubin lab at Harvard University, identified pesticides that could be relevant to the development of Parkinson’s disease. The study was led by Richard Krolewski, MD, PhD, a neurologist in the Brigham’s Division of Movement Disorders and Ann Romney Center for Neurologic Diseases, and Kimberly ...

Results of SWOG S1929 trial show patients with small-cell lung cancer with SLFN11 expression can benefit from PARP inhibitor added to immune checkpoint blockade

2023-06-02

Among patients with extensive stage small-cell lung cancer (SCLC) that is positive for expression of the Schlafen-11 gene (SLFN11), those who received maintenance atezolizumab immunotherapy plus the PARP inhibitor talazoparib had significantly longer progression-free survival (PFS) times than those who received atezolizumab alone (median PFS 4.2 months versus 2.8 months). These results from the phase II S1929 trial conducted by the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), will be reported ...

UCSF Health Cancer experts featured at premier cancer meeting

2023-06-02

Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education. The theme this year is Partnering With Patients: The Cornerstone of Cancer Care and Research. More than 30,000 people are expected to attend the meeting taking place in Chicago and online June 2-6, 2023. “As the world’s leading clinical cancer meeting, ASCO is an important event for oncology professionals to share information on the latest ...

Multiple sclerosis more prevalent in Black Americans than previously thought

2023-06-02

Multiple sclerosis has traditionally been considered a condition that predominantly affects white people of European ancestry. However, a new analysis conducted by a North American team led by University of Maryland School of Medicine (UMSOM) researchers suggests that the debilitating neurological condition is more prevalent in Black Americans than once thought. It is also far more prevalent in Northern regions of the country including New England, the Dakotas, and the Pacific Northwest. Findings from the new study were recently published in the journal JAMA Neurology. “We found a much higher prevalence of multiple sclerosis in Black Americans than previously ...

Sensory adapted dental rooms significantly reduce autistic children’s physiological and behavioral stress during teeth cleanings

2023-06-02

New results from a study led by USC researchers at Children’s Hospital Los Angeles show that a sensory adapted dental clinic environment creates less distressing oral care experiences for autistic children. The open-access article is available today in JAMA Network Open. “We’ve shown that the combination of curated visual, auditory and tactile adaptations — all of which are easily implemented, relatively inexpensive and don’t require training to safely use — led to statistically significant decreases in autistic children’s behavioral ...

Couples’ social networks took long-lasting hit during COVID

2023-06-02

Key takeaways: A UCLA study shows that a the outset of the COVID-19 pandemic, social interactions, both virtual and in person, declined significantly for married couples. The decline was found to be greater and more long-lasting for Black and Latino couples and lower-income couples than for white couples and wealthier couples. The researchers suggest exploring new ways of protecting public health during crises that also help more vulnerable populations sustain meaningful relationships. Following the lockdowns and restrictions on public gatherings in the early days of COVID-19, the social networks of white, ...

AI software can provide ‘roadmap’ for biological discoveries

2023-06-02

Predicting a protein’s location within a cell can help researchers unlock a plethora of biological information that’s critical for developing future scientific discoveries related to drug development and treating diseases like epilepsy. That’s because proteins are the body’s “workhorses,” largely responsible for most cellular functions. Recently, Dong Xu, Curators Distinguished Professor in the Department of Electrical Engineering and Computer Science at the University of Missouri, and colleagues updated their protein localization prediction model, MULocDeep, ...

Study helps explain what drives psoriasis severity and offers clues as to how disease may spread to other body parts

2023-06-02

Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by the activity of key cells and signaling pathways, a new study shows. Led by researchers at NYU Grossman School of Medicine, the study mapped hidden features of inflammation and how they compared in cases of increasing severity of psoriatic disease. The team’s findings may help explain how small areas of skin inflammation can have wide-ranging effects in other parts of the body. Up to one-fifth of those with the skin disease, the researchers note, ...